HCC risk prediction may be poorly reported and biased for individuals with nonviral chronic liver disease.
Similar percentages of patients with PsA receiving secukinumab vs adalimumab achieved an ACR20 response at 12 weeks.
The prevalence of diabetes was 15.8 percent among U.S. adults during August 2021 to August 2023, according to a November data brief published by the National Ce ...
The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of the active ingredient in those medications have now been linked to at least ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback